Hvidovre, Denmark
Hvidovre, Denmark

Time filter

Source Type

Patent
Hvidovre Hospital | Date: 2015-07-10

The present disclosure relates to ascoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane. The disclosure furthermore relates to a method for manufacturing a scoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane and a method for reducing risk and/or treating spinal deformities, such as scoliosis, of a patient by applying pressure to the thoracic spine of the patient, such that the thoracic spine of the patient is bent forward in the sagittal plane.


Patent
Hvidovre Hospital | Date: 2017-05-24

The present disclosure relates to ascoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane. The disclosure furthermore relates to a method for manufacturing a scoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane and a method for reducing risk and/or treating spinal deformities, such as scoliosis, of a patient by applying pressure to the thoracic spine of the patient, such that the thoracic spine of the patient is bent forward in the sagittal plane.


The present invention relates to methods for obtaining a whole virus vaccine candidate stock. The present invention also relates to an inactivated whole virus vaccine candidate stock that can be used for vaccination purposes as well as development of novel high titer virus, which is the preferred virus for this technique.


Patent
Hvidovre Hospital and R.Ø.S.A. | Date: 2013-04-10

The present invention relates to a transmural, self-expanding biodegradable stent (1) for the use of treating collections complicating acute and chronic pancreatitis. The stent is compressible for insertion through the gastric or duodenal wall and into the collections. The stent expands after insertion to stay in place by the specific dimensions of the stent.


Pachler J.,Hvidovre Hospital
Cochrane database of systematic reviews (Online) | Year: 2012

For almost one hundred years abdominoperineal excision has been the standard treatment of choice for rectal cancer. With advances in the techniques for rectal resection and anastomosis, anterior resection with preservation of the sphincter function has become the preferred treatment for rectal cancers, except for those cancers very close to the anal sphincter. The main reason for this has been the conviction that the quality of life for patients with a colostomy after abdominoperineal excision was poorer than for patients undergoing an operation with a sphincter-preserving technique. However, patients having sphincter-preserving operations may experience symptoms affecting their quality of life that are different from stoma-patients. To compare the quality of life in rectal cancer patients with or without permanent colostomy. We searched PUBMED, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Colorectal Cancer Group's specialised register. Abstract books from major gastroenterological and colorectal congresses were searched. Reference lists of the selected articles were scrutinized. All controlled clinical trials and observational studies in which quality of life was measured in patients with rectal cancer having either abdominoperineal excision/Hartmann's operation or low anterior resection, using a validated quality of life instrument, were considered. One reviewer (JP) checked the titles and abstracts identified from the databases and hand search. Full text copies of all studies of possible relevance were obtained. The reviewer decided which studies met the inclusion criteria. Both reviewers independently extracted data. If information was insufficient the original author was contacted to obtain missing data. Extracted data were cross-checked and discrepancies resolved by consensus. Sixty-nine potential studies were identified. Thirty-five of these, all non-randomised and representing 5127 participants met the inclusion criteria. Fourteen trials found that people undergoing abdominoperineal excision/Hartmann's operation did not have poorer quality of life measures than patients undergoing anterior resection. The rest of the studies found some difference, but not always in favour of non-stoma patients. Due to clinical heterogeneity and the fact that all studies were observational trials, meta-analysis of the included studies was not possible. The studies included in this review do not allow firm conclusions as to the question of whether the quality of life of people after anterior resection is superior to that of people after abdominoperineal excision/Hartmann's operation. The included studies challenges the assumption that anterior resection patients fare better. Larger, better designed and executed prospective studies are needed to answer this question.


The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.


Patent
Hvidovre Hospital | Date: 2014-06-23

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.


Patent
Hvidovre Hospital and United States Of America As Represented By The Secretary | Date: 2014-10-14

The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.


The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) of genotype 2b that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs, which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.


Patent
Hvidovre Hospital | Date: 2014-10-21

The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.

Loading Hvidovre Hospital collaborators
Loading Hvidovre Hospital collaborators